Add BrightSurf on Google Email

Revealed: How SARS-CoV-2 evades our immune system

Researchers at Hokkaido University and Texas A¼M University identified a key mechanism used by SARS-CoV-2 to evade host immune systems, targeting the MHC class I pathway. The study found that the virus suppresses the activation of this pathway using the ORF6 protein, allowing it to persist in the body and infect others.

SourceHokkaido University·JournalNature Communications·TypeData/statistical analysis·DateDec 7, 2021

Severe COVID could reduce male fertility

A recent study suggests that severe COVID-19 may cause long-term damage to the testes, leading to reduced sperm count and quality. The virus's interaction with testicular cells and potential effects on fertility are being explored through an experimental framework.

SourceUniversity of Georgia·JournalNature Reviews Urology·DateDec 7, 2021

Large field hospital study shows rapid Covid-19 test compares solidly with PCR detection

A large field hospital study shows that a rapid Covid-19 test is as accurate as PCR detection, with high sensitivity rates for both symptomatic and asymptomatic patients. The rapid antigen test's ease of use, time savings, and cost effectiveness make it an ideal solution to reduce testing disparities in medically underserved communities.

SourceJohns Hopkins Medicine·JournalMicrobiology Spectrum·DateDec 7, 2021

Impact of obesity and metabolic disorders on severity of COVID-19 and vaccine-breakthrough infections

A study found that obesity is associated with severe COVID-19 outcomes, including hospital admission or death. Additionally, accelerated immunosenescence may be a key mechanism explaining the relationship between obesity and T2DM in severe COVID-19. Vaccination effectiveness may also be impacted by metabolic disorders.

SourceDeutsches Zentrum fuer Diabetesforschung DZD·JournalNature Reviews Endocrinology·TypeSystematic review·DateDec 7, 2021

New vaccine ingredient shows promise

Scientists at La Jolla Institute for Immunology and MIT have discovered a new adjuvant called SMNP, which combines saponin and TLR agonist to boost the protective power of vaccines. The study found that SMNP triggers a strong immune response in mice, promoting lymphatic drainage and activating multiple parts of the immune system.

SourceLa Jolla Institute for Immunology·JournalScience Immunology·TypeExperimental study·DateDec 3, 2021

‘Immune imprinting’ by different SARS-CoV-2 spike sequences from variants and vaccines means we now have diverse patterns of protection against new variants

A study by Imperial College London found that the first SARS-CoV-2 spike protein encountered through vaccination or infection influences subsequent immune responses to current and future variants. This 'immune imprinting' affects the rate of decay of protection and impacts antibody levels over time.

SourceImperial College London·JournalScience·TypeObservational study·DateDec 2, 2021

Georgia State University Center for Translational Antiviral Research reports a novel broad-spectrum antiviral drug class with activity against SARS-CoV-2

Researchers at Georgia State University have developed a new candidate antiviral drug, 4’-FlU, which shows potent activity against SARS-CoV-2 and other respiratory RNA viruses. The study demonstrates that 4’-FlU induces termination of the viral polymerase, aborting replication and offering a strong therapeutic asset.

SourceGeorgia State University·JournalScience·TypeExperimental study·DateDec 2, 2021

Evasive maneuvers

Researchers at Harvard Medical School identified likely mutations that would allow the virus to evade immune defenses, including natural immunity and vaccine-developed antibodies. The study provides important clues about areas of concern with omicron variant and serves as a primer for future variants.

SourceHarvard Medical School·JournalScience·DateDec 2, 2021

Which COVID-19 vaccine works better?

The study found that the Moderna vaccine offered a lower risk of documented infection (21% reduced), symptomatic COVID-19 (44% reduced), hospitalization (55% reduced), ICU admission (10% reduced), and death (2% reduced) compared to the Pfizer vaccine. The results suggest that either vaccine is effective, but Moderna may be slightly mor...

SourceVeterans Affairs Research Communications·JournalNew England Journal of Medicine·TypeNews article·DateDec 1, 2021

Viral evolution in animals could reveal future of COVID-19

A recent study by Colorado State University researchers found that COVID-19 can evolve and spread rapidly among animal species after infection from humans. The team analyzed mutation types occurring in cats, dogs, ferrets, and hamsters, discovering a broad range of viral variants that emerged and became prevalent.

SourceColorado State University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateDec 1, 2021

ComCor study: New results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant

The study found that indoor bars, private parties, and nightclubs were high-risk places for transmitting the Delta variant, with men being more susceptible. Previous infection conferred a 95% protective effect, while two doses of mRNA vaccines provided 67% protection against symptomatic infection.

SourceInstitut Pasteur·TypeCase study·DateNov 30, 2021

Taking new aim at COVID-19

Researchers at Duke University have identified chemical compounds that can latch onto the coronavirus's 3D RNA structures and block replication. The compounds, which target the virus's RNA specifically, offer a new mechanism of action against COVID-19.

SourceDuke University·JournalScience Advances·TypeExperimental study·DateNov 26, 2021

UK study suggests COVID-19 became much more lethal in late 2020

A new statistical analysis supports the notion that COVID-19 became more lethal in the UK in late 2020, with increased lethality attributed to factors beyond just the alpha variant of the virus. The study used Bayesian inference to draw stronger conclusions from weekly data on cases and deaths.

SourcePLOS·JournalPLOS ONE·TypeComputational simulation/modeling·DateNov 24, 2021

New precision approach against coronavirus infection: How the ACE2 receptor blocks the 'gateway' into human cells

Researchers from Istituto Italiano di Tecnologia have developed a new precision strategy to hinder coronavirus infection by blocking the ACE2 receptor. The study, published in Pharmacological Research, reveals two anti-K353 aptamers that dose-dependently inhibit viral spike protein binding to human ACE2, preventing cell infection.

SourceIstituto Italiano di Tecnologia - IIT·JournalPharmacological Research·TypeExperimental study·DateNov 23, 2021

The Lancet Infectious Diseases: First real-world study reports effectiveness of BBV152 against symptomatic COVID-19 in India

A real-world study of BBV152 found that two doses resulted in 50% effectiveness against symptomatic COVID-19 in hospital workers. The study's findings support the importance of a second dose for maximum protection, but highlight limitations in estimating vaccine effectiveness against severe outcomes.

SourceThe Lancet·JournalThe Lancet Infectious Diseases·TypeObservational study·DateNov 23, 2021

COVID gets airborne

UC San Diego researchers developed a computer model to understand how viruses travel through the air, shedding new light on airborne COVID-19 transmission. The model simulates aerosol behavior and helps explain why SARS-CoV-2 is highly transmissible through the air.

SourceUniversity of California - San Diego·TypeComputational simulation/modeling·DateNov 22, 2021

How well do wet masks contain droplets?

Researchers found that wet masks make it more difficult for respiratory droplets to penetrate and escape the mask, splintering into smaller aerosolized particles. This is because wet masks create additional resistance due to their hydrophobic or hydrophilic materials, making them more effective at stopping droplet penetration.

SourceUniversity of California - San Diego·JournalPhysical Review Fluids·TypeExperimental study·DateNov 22, 2021

COVID-19 testing kits also can measure oral microbiome in saliva

A Rutgers study found that COVID-19 saliva testing kits with a preservative can accurately measure the oral microbiome, which may lead to new treatments for lung health in people with COVID-19. The study collected saliva samples from participants and compared their ability to measure microbes before and after COVID-19 infection.

SourceRutgers University·Journalnpj Biofilms and Microbiomes·TypeExperimental study·DateNov 22, 2021

Plant-derived antiviral drug is effective in blocking highly infectious SARS-CoV-2 Delta variant, say scientists

Scientists at the University of Nottingham found a plant-based antiviral treatment to be effective in blocking the highly infectious SARS-CoV-2 Delta variant. The novel natural antiviral drug, thapsigargin, was shown to trigger a broad-spectrum host-centred antiviral innate immune response against all variants of the virus.

SourceUniversity of Nottingham·JournalVirulence·TypeExperimental study·DateNov 19, 2021

Unborn babies could contract Covid-19 says study, but it would be uncommon

A new study suggests that unborn babies could contract Covid-19 if their gut is exposed to the SARS-CoV-2 virus. However, researchers say that this risk is extremely limited due to the placenta's protective shield. Vaccination against Covid-19 during pregnancy is still recommended as a way to protect the unborn baby.

SourceUniversity College London·JournalBJOG An International Journal of Obstetrics & Gynaecology·TypeObservational study·DateNov 19, 2021

Delta-like SARS-CoV-2 variants are most likely to increase pandemic severity

A mathematical model suggests that SARS-CoV-2 Delta-like variants, which combine enhanced transmissibility and partial immune escape, will cause more severe pandemics than variants with either trait alone. Vaccination is predicted to be highly beneficial in these cases, preventing more infections and breakthroughs.

SourceHarvard T.H. Chan School of Public Health·JournalCell·TypeComputational simulation/modeling·DateNov 19, 2021

The number of SARS-CoV-2 infections among vaccinated people could be overestimated unless appropriate diagnostic tests are used, says ISGlobal study

Research team discovered mRNA vaccines induce antibodies recognizing Spike and N protein fragments, potentially leading to misclassified breakthrough infections. The study suggests using multiple viral antigens for accurate detection of vaccine effectiveness.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalTranslational Research·TypeData/statistical analysis·DateNov 18, 2021

Air pollution does not increase the risk of getting infected but does increase the risk of getting sick from COVID-19

A study found that long-term exposure to air pollution increases the risk of developing COVID-19 symptoms, especially among older men and those living in poverty. However, no association was found between infection and exposure to air pollutants.

SourceBarcelona Institute for Global Health (ISGlobal)·JournalEnvironmental Health Perspectives·TypeExperimental study·DateNov 17, 2021

Machine learning IDs mammal species with the potential to spread SARS-CoV-2

A new study used machine learning to predict the zoonotic capacity of 5,400 mammal species, identifying those at high risk of transmitting SARS-CoV-2. The model, which combined data on biological traits with ACE2 receptor information, predicted 72% accuracy and identified numerous additional species with potential to transmit the virus.

SourceCary Institute of Ecosystem Studies·JournalProceedings of the Royal Society B Biological Sciences·TypeComputational simulation/modeling·DateNov 16, 2021

Study shows immune cells against COVID-19 stay high in number six months after vaccination

Researchers found that CD4+ T lymphocytes — immune system cells — produced by people who received COVID-19 vaccines persisted at high levels six months after vaccination, with a significant response against the delta variant. The study also showed that vaccine-elicited fighters recognize and help attack coronavirus delta variant.

SourceJohns Hopkins Medicine·JournalClinical Infectious Diseases·DateNov 16, 2021